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Abstract
Introduction High hospital case volumes are associated with improved treatment outcomes for numerous diseases. We 
assessed the association between academic non-profit hospital case volume and survival of adult glioblastoma patients.
Methods From the nationwide Finnish Cancer Registry, we identified all adult (≥ 18 years) patients with histopathological 
diagnoses of glioblastoma from 2000 to 2013. Five university hospitals (treating all glioblastoma patients in Finland) were 
classified as high-volume (one hospital), middle-volume (one hospital), and low-volume (three hospitals) based on their 
annual numbers of cases. We estimated one-year survival rates, estimated median overall survival times, and compared 
relative excess risk (RER) of death between high, middle, and low-volume hospitals.
Results A total of 2,045 patients were included. The mean numbers of annually treated patients were 54, 40, and 17 in the 
high, middle, and low-volume hospitals, respectively. One-year survival rates and median survival times were higher and 
longer in the high-volume (39%, 9.3 months) and medium-volume (38%, 8.9 months) hospitals than in the low-volume (32%, 
7.8 months) hospitals. RER of death was higher in the low-volume hospitals than in the high-volume hospital (RER = 1.19, 
95% CI 1.07–1.32, p = 0.002). There was no difference in RER of death between the high-volume and medium-volume 
hospitals (p = 0.690).
Conclusion Higher glioblastoma case volumes were associated with improved survival. Future studies should assess whether 
this association is due to differences in patient-specific factors or treatment quality.
Keywords Glioblastoma · Glioma · Malignant glioma · Epidemiological study · Mortality · Outcome
Introduction
Glioblastoma is the most common malignant brain tumor 
to be newly diagnosed in adults [1]. The aim of treatment 
of newly diagnosed glioblastomas is palliative, consisting 
of maximal surgical resection and, since 2005, consisting Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s1106 0-020-03428 -5) contains 
supplementary material, which is available to authorized users.
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of adjuvant concomitant chemoradiation including temo-
zolomide followed by cycles of temozolomide chemother-
apy (i.e., the Stupp regimen) [2, 3]. Still, glioblastoma is 
rare with an incidence of approximately 3/100,000 [4]. 
Thus, most hospitals see only a few cases every year [5].
In general, hospital volume is frequently associated 
with various treatment outcomes. Studies of glioblastoma 
treatment have suggested that survival is improved in high-
volume and academic centers [5–9]. However, reliable 
comparisons between hospitals have been challenging to 
conduct due to the vast heterogeneity in case-mix between 
hospitals. Socioeconomic factors and personal insurance, 
for instance, have a strong influence on glioblastoma treat-
ment and survival in many countries [10]. Given that Fin-
land has the largest human capital [11], one of the highest 
cancer survival rates [12], and one of the highest health 
access and quality indexes in the world [13] as well as a 
tax-funded universal healthcare system, Finland may be 
considered an optimal country for investigating any vol-
ume-outcome associations concerning cancer treatments.
The aim of the present nationwide study was to assess 
the association between hospital case volume and glioblas-
toma survival. Due to the reasons mentioned above, and 
since glioblastoma treatment in Finland has been central-
ized for decades into five non-profit and relatively similar 
academic hospitals (with each hospital covering its own 
population), we believe that any significant effect of case 
volume on glioblastoma survival is best demonstrated 
using nationwide Finnish data. Our null hypothesis was 
that case volume does not influence glioblastoma survival.
Methods
Study setting
In Finland, five non-profit academic university hospitals 
(in Helsinki, Tampere, Turku, Kuopio and Oulu) provide 
all intracranial surgeries, including glioblastoma resec-
tions and biopsies, for their given catchment areas. The 
Finnish public healthcare system offers equal access to 
low-cost healthcare. In 2019, for example, the daily fee 
for short-term institutional care at Helsinki University 
Hospital was €48.90 with a maximum out-of-pocket pay-
ment limit of €683.00 per calendar year. This upper limit 
included everything from all types of surgery to intensive 
care unit stays, radiotherapy, and so forth. Furthermore, 
temozolomide treatment is covered by the Social Insurance 
Institute KELA with a maximum out-of-pocket payment of 
€50 per calendar year plus €4.50 for every temozolomide 
purchase (independent of the amount purchased).
Finnish Cancer Registry
We have previously described the Finnish Cancer Registry 
(FCR) in detail [4]. In short, the FCR is a national register 
that includes all cancers diagnosed since 1953 in Finland. 
The FCR’s coverage is high, encompassing 96% of solid 
tumors and 95% of all cases of cancer diagnosed in Finland 
[14]. The data of the FCR is regularly linked with the Popu-
lation Register for date of death or emigration and with Sta-
tistics Finland for cause of death. Cancer coding follows the 
nomenclature and coding rules of the International Classi-
fication of Diseases for Oncology Third Edition (ICD-O-3).
Identification of glioblastoma patients from the FCR
We identified patients aged ≥ 18 years with histopathological 
(by biopsy or resection) diagnoses of primary glioblastoma 
using the ICD-O-3 topography codes “C71.0–71.9” and the 
respective morphology code “9440”. We did not consider 
morphology codes “9441” (giant cell glioblastoma, N = 25) 
and “9442” (gliofibroma/gliosarcoma, N = 58). We did not 
include secondary glioblastomas (previously diagnosed 
grade II–III gliomas), recurrent glioblastomas, or death-
certificate-only (DCO) cases. We have previously shown that 
the search strategy used in the present study is 97% accurate 
in identifying glioblastoma cases from the FCR [4].
Follow‑up
We defined survival time as the amount of time from his-
topathological diagnosis to death. We followed all patients 
until death, emigration, or the end of 2015, whichever was 
earliest. No cases were lost to follow-up.
Statistical analyses
We divided the five aforementioned academic hospitals 
into three groups (high-volume, medium-volume, and low-
volume) based on the numbers of diagnosed glioblastoma 
patients in the five catchment areas. This categorization was 
based upon our previous paper [4].
We calculated age-standardized glioblastoma incidence 
per 100,000 inhabitants using the European Standard Pop-
ulation 2013 (ESP2013). We reported the incidence rates 
separately for individuals aged between 18 and 70 years and 
those aged over 70 years. We also reported the incidence 
rates separately for the high, medium, and low-volume hos-
pitals. We estimated the relative annual change in the age-
standardized incidence rate using a Poisson regression. We 
used the Davies’ test as a significance test to detect changes 
in the incidence trend [15].
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We calculated age-standardized relative survival rates 
using the Ederer II method, which summarizes patients’ 
relative excess risk (RER) of death due to cancer by com-
paring patient survival to that of the reference population 
(the population of the hospital area stratified by sex, age, 
and calendar year) [16]. For age standardization, we used 
the age-group-specific numbers of patients diagnosed in Fin-
land in 2000–2013 as weights in six groups (18–40, 41–50, 
51–60, 61–70, 71–80, and 81 years or older at diagnosis).
We compared differences in relative survival between 
patients diagnosed in the different hospitals by calculat-
ing RER using a Poisson regression model for relative sur-
vival [17]. This model included seven intervals of follow-
up time since diagnosis (0 to < 2 months, 2 to < 6 months, 
6 to < 12 months, 12 to < 18 months, 18 to < 24 months, 2 
to < 3 years, and 3 to < 5 years), age at diagnosis (the same 
age groups as in the age standardization), and case volume 
group. Interaction between follow-up time and age was also 
included to allow for non-proportional RER of death by age. 
The first five years of follow-up were considered, and longer 
survival times were censored at five years. We used the high-
case-volume hospital as the point of reference. Thus, an RER 
under one would indicate that the RER of death is lower 
than that in the high-case-volume hospital, and conversely, 
an RER over one would indicate that the RER of death is 
higher than that in the high-case-volume hospital. We tested 
differences in RER of death between the hospitals using a 
likelihood-ratio test. The p values were adjusted for multi-
ple comparisons using the method of Benjamini and Hoch-
berg [18]. Given the distinct differences in survival between 
patients diagnosed from 2000–2006 and from 2007–2013, 
as well as the differences in survival between patients under 
and over 70 years of age [4], these time periods and age 
groups were analyzed separately. We also described differ-




One hospital was considered to be high-volume (mean 
annual case volume = 54, total case volume = 761, mean 
population = 1,782,070), one hospital was considered to 
be medium-volume (mean annual case volume = 40, total 
case volume = 560, mean population = 1,228,294), and three 
hospitals were considered to be low-volume (mean annual 
case volume = 17, mean total case volume = 241 per hospital, 
mean population = 750,948, range 701,566–821,218). Of the 
total Finnish population, 34% lived in a high-volume hospi-
tal region, 23% lived in a medium-volume hospital region, 
and 43% lived in low-volume hospital regions (Fig. 1).
Patients
We identified 2045 patients with primary glioblastoma 
diagnosed between 2000 and 2013. The mean and median 
ages were 62.8 and 63.3 years, respectively. Further, 25% of 
the patients were older than 70 years of age and 42% were 
female. There were no noticeable differences in age or sex 
distribution between the high and medium-volume hospi-
tals. Patients treated in low-volume hospitals were slightly 
younger and more often male than those in the medium and 
high-volume hospitals (Table 1).
Incidence
The mean age-standardized incidences of glioblastoma for 
those living in high-volume, median-volume, and low-vol-
ume hospital regions were 3.5/100,000, 3.3/100,000, and 
2.3/100,000, respectively (Table 2). Throughout the whole 
study period, the mean annual age-standardized incidence 
rate of glioblastoma increased in the high-volume hospi-
tal region by 3.0% per year (95% CI 1.2–4.9, Davies’ test 
p = 0.33) but did not change in the medium-volume hos-
pital region (0.7%, 95% CI − 1.4 to 2.8 per year, Davies’ 
test p = 0.11) nor in the low-volume hospital regions (0.8%, 
95% CI − 1.0 to 2.7 per year, Davies’ test p = 0.90; Fig. 2). 
The increase in the overall incidence of glioblastoma in the 
high-volume hospital was mainly due to an increase in the 
incidence of elderly patients (> 70 years of age; Fig. 2).
For patients over 70 years of age, the glioblastoma inci-
dence rate was clearly lower in both the medium-volume 
(7.1 per 100,000) and low-volume (4.6 per 100,000) hospi-
tal regions than in the high-volume hospital region (9.1 per 
100,000; Table 2). For patients 70 years of age or younger, 
the glioblastoma incidence rate was lower in the low-volume 
hospital region (2.0 per 100,000) than in the high-volume 
(2.7 per 100,000) and medium-volume (2.8 per 100,000) 
hospital regions.
Within the hospital region, the incidence of glioblas-
toma increased only in the high-volume region from the 
period of 2000–2006 to the period of 2007–2013 (for 
patients ≤ 70 years of age, incidence rate ratio = 1.25, 95% 
CI 1.05–1.47; for patients > 70 years of age, incidence rate 
ratio = 1.47, 95% CI 1.10–1.95; Online Resource 2).
Survival
The one-year survival rates in the high-volume, medium-
volume, and low-volume hospitals were 39%, 38%, and 
32%, respectively. One-year survival rates increased from 
the period of 2000–2006 to the period of 2007–2013, 
regardless of case volume (Table 3). From 2007–2013, the 
one-year survival rates for patients aged ≤ 70 years ranged 
between 47 and 52%. The one-year survival rates of patients 
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aged > 70 years ranged from 11% in the low-volume hospital 
to 19% in the medium-volume hospital.
The overall survival times ranged from 7.8 months in the 
low-volume hospital to 9.3 months in the high-volume hos-
pital (Fig. 3). From the period of 2000–2006 to the period 
of 2007–2013, median survival times increased for all age 
groups, regardless of case volume (Table 3, Fig. 4). From 
2007–2013, the median survival times for ≤ 70-year-old 
patients ranged between 11.2 months and 12.4 months. For 
patients aged > 70 years, median survival times ranged from 
4.0 months to 4.8 months (Table 3).
RER of death was higher in the low-volume hospitals 
than in the high-volume hospital throughout the study 
period (Table 4). Throughout the whole study period, RER 
of death was 19% (95% CI 7–32, p = 0.002) higher in the 
Fig. 1  Proportion of persons 
living in high, medium, and 
low-volume hospital regions 
in Finland. Finland’s map to 
the left: people living in the 
red areas are being treated in 
low-volume hospitals, people 
living in the blue area are being 
treated in a medium-volume 
hospital, and people living in 
the green area are being treated 
in a high-volume hospital. Stars 
represent the locations of the 
five university hospitals. To the 
right: population distribution 
according to age in areas cov-
ered by a high-volume hospital 
(green), a medium-volume 
hospital (blue), and the mean of 
the low-volume hospitals (red). 
Number and proportion of per-
sons < 18 years of age (bottom), 
18–70 years of age (middle), 
and > 70 years of age (top)
Table 1  Differences in patient characteristics according to case vol-
ume
Categorical variables shown as numbers with percentages. Data from 
the Finnish Cancer Registry




ume (N = 560)
Low-volumea
(N = 724)
Age, year, mean 63.4 62.7 62.3
Age, year, median 63.3 63.2 63.2
 ≤ 70 year 556 (73%) 416 (74%) 554 (77%)
 > 70 year 205 (27%) 144 (26%) 170 (23%)
Sex
 Women 334 (44%) 238 (43%) 282 (39%)
 Men 427 (56%) 322 (57%) 442 (61%)
Time of diagnosis
 2000–2006 304 (40%) 262 (47%) 327 (55%)
 2007–2013 457 (60%) 298 (53%) 397 (45%)
Table 2  Age-standardized incidence rates and incidence rate ratios by 
case volume
Age standardization according to the European Standard Population 
2013 per 100,000 people
High-volume hospital used as reference for the incidence rate ratio 
comparisons. An incidence rate ratio over 1 indicates a higher inci-
dence than the reference
Age standardized Incidence (95% CI)
Age group High-volume Medium-volume Low-volume
All 3.5 (3.3–3.8) 3.3 (3.1–3.6) 2.3 (2.2–2.5)
 ≤ 70 years 2.7 (2.5–2.9) 2.8 (2.5–3.0) 2.0 (1.8–2.2)
 > 70 years 9.1 (7.9–10.4) 7.1 (6.0–8.4) 4.6 (4.0–5.4)
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low-volume hospitals than in the high-volume hospital. For 
patients aged ≤ 70 years, RER of death was 20% higher (95% 
CI 6–35, p = 0.016) in the low-volume hospitals than in the 
high-volume hospital. For patients aged > 70 years, RER of 
death was 18% higher (95% CI − 5 to 45) in the low-volume 
hospitals than in the high-volume hospital, but this did not 
reach statistical significance (p = 0.266). There was no sta-
tistically significant difference in RER of death between the 
high-volume and medium-volume hospitals.
Discussion
In this nationwide study, we found that patients with newly 
diagnosed glioblastoma had a 19% (7% to 32%) higher RER 
of death when treated in a low-volume hospital than when 
treated in a high-volume hospital. Differences in survival, 
particularly among ≤ 70-year-old glioblastoma patients, 
seemed to explain this case-volume-associated finding (20%, 
95% CI 6–35, higher RER of death when treated in low-
volume hospitals vs. high-volume hospitals). We found no 
difference in survival between the high-volume and medium-
volume hospitals. In addition, we found notable differences 
Fig. 2  Trends in age-standardized glioblastoma incidence rates from 
2000 to 2013 by case volume. From left to right: all age groups, 
elderly patients (> 70 years of age) and younger patients (≤ 70 years 
of age). The overall incidence of glioblastoma increased in the high-
volume hospital but remained the same in the medium-volume and 
low-volume hospitals. Still, the incidence of glioblastoma in the 
medium-volume hospital increased markedly from 2011 onward
Table 3  One-year survival and overall survival according to hospital case volume status
One-year survival shown as percentages with 95% confidence intervals (CI)
Overall survival shown as medians with 95% CIs
One-year survival (%, 95% CI) Overall survival (months, 95% CI)
2000–2006 2007–2013 2000–2013 2000–2006 2007–2013 2000–2013
All patients
 High-volume 34 (29–39) 43 (39–47) 39 (36–42) 8.7 (7.6–9.7) 9.9 (9.0–11.1) 9.3 (8.7–10.1)
 Medium-volume 34 (28–39) 42 (37–47) 38 (32–42) 7.5 (6.4–8.7) 10.1 (9.0–11.2) 8.9 (8.2–9.8)
 Low-volume 27 (22–31) 38 (33–42) 32 (29–35) 6.4 (5.5–7.7) 9.0 (7.8–9.8) 7.8 (7.1–8.6)
Age group ≤ 70 years
 High-volume 42 (36–48) 52 (46–57) 48 (44–52) 10.2 (8.9–11.6) 12.4 (11.0–14.2) 11.4 (10.3–12.3)
 Medium-volume 42 (35–49) 50 (43–56) 46 (41–51) 9.4 (7.9–11.4) 11.9 (10.6–13.2) 11.0 (9.9–12.1)
 Low-volume 34 (28–39) 47 (41–52) 40 (36–44) 8.6 (7.1–9.8) 11.2 (9.9–12.4) 9.8 (9.1–10.6)
Age group > 70 years
 High-volume 9 (4–17) 17 (11–24) 13 (9–18) 3.8 (2.9–4.8) 4.8 (3.9–5.8) 4.3 (3.6–4.9)
 Medium-volume 10 (4–19) 19 (12–28) 16 (10–22) 3.8 (3.1–5.5) 4.3 (3.3–5.4) 3.9 (3.4–5.1)
 Low-volume 7 (3–14) 11 (6–18) 10 (6–15) 3.3 (2.4–4.0) 4.0 (3.1–5.4) 3.6 (3.1–5.1)
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in the incidence of operated glioblastomas between different 
case volumes.
A positive correlation between higher hospital case vol-
umes and improved outcomes has been reported for several 
cardiovascular and oncological procedures [19–21]. Recent 
studies from the United States have shown improved sur-
vival rates for glioblastoma patients treated in centers with 
more than 23–30 cases per year [5–7]. This finding is in line 
with our present results, as the mean case volume for the 
small-volume hospitals was 17 patients, whereas those of the 
medium and high-volume hospitals were 40 and 54, respec-
tively. Unlike previous studies, our study analyzed RER of 
death by case volume and case-volume-related survival prior 
to and after the introduction of the Stupp regimen in 2005 
[2]. Perhaps most importantly, we also analyzed case-vol-
ume-related survival differences among elderly (> 70-year-
old) glioblastoma patients, since they likely comprise the 
fastest growing group of glioblastoma patients [4]. We did 
not find a statistically significant association between case 
volume and survival for elderly patients, whereas a higher 
case volume was significantly associated with higher sur-
vival in younger patients. Still, the RER estimate for elderly 
patients was similar to the RER estimate for ≤ 70-year-old 
glioblastoma patients but did not reach statistical signifi-
cance. This result may have been related to the cohort size 
resulting in limited statistical power.
In the high-volume hospital region, there was an increase 
in the incidence of histopathologically confirmed glioblas-
toma following the publication of the EORTC-NCIC trial 
[2]. Reasons for this are unclear, but more rapid implemen-
tation of new forms of chemotherapy, including temozolo-
mide, may have led to more active histologic confirmation of 
glioblastoma diagnoses, especially among elderly patients in 
the high-volume hospital. In other words, when new, promis-
ing treatment results were introduced, the results may have 
been extrapolated as a new standard for elderly glioblastoma 
patients even though the trial [2] did not include any elderly 
patients. This means that elderly patients may have been 
considered as candidates for temozolomide, but only in cases 
where the diagnosis was histopathologically confirmed. In 
fact, only 13% of elderly glioblastoma patients received 
temozolomide in the high-volume hospital in 2005, whereas 
33% received temozolomide in 2010 [4]. Thus, differences in 
the incidence of histopathologically confirmed glioblastoma 
might reflect a more active diagnostic policy (i.e., lower 
thresholds for biopsy or resection to obtain histopathological 
confirmation) for elderly glioblastoma patients in the high-
volume hospital. However, lowering treatment thresholds 
could lead to lower survival rates, presuming that the quality 
of glioblastoma treatment is similar among different study 
centers. On the other hand, a more active treatment policy 
Fig. 3  Difference in relative survival between high-volume, medium-
volume, and low-volume hospitals (2000–2013). Median overall sur-
vival time was longest in the high-volume hospital (9.3 months), fol-
lowed by that in the medium-volume hospital (8.9 months) and that in 
the low-volume hospitals (7.8 months)
Fig. 4  Relative survival by volume status (high to the left, medium in the middle, and low to the right) in the periods of 2000–2006 and 2007–
2013, separately for patients aged ≤ 70 and > 70 years
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could also cause more patients to undergo tumor resection 
and actually receive post-operative chemoradiation,this 
should improve survival [22]. In fact, nearly all elderly glio-
blastoma patients underwent resections in the high-volume 
hospital [4], whereas the balance between resections and 
biopsies in the medium-volume and low-volume hospitals 
remains unknown. Further studies are needed to pinpoint 
differences in treatment thresholds and given treatments that 
may explain the noted differences.
Differences in the incidence of histopathologically diag-
nosed glioblastoma and survival may also be consequences 
of differences in other health-related factors, differences in 
access to care, and differences in true glioblastoma inci-
dence. However, as there are no widely accepted, common 
risk factors for glioblastoma (except for age), true age-
adjusted regional differences in glioblastoma incidence are 
unlikely. Nevertheless, Finland has a relatively stable gene 
pool compared to other European countries, with some 
genetically isolated populations (for example, in Northern 
and Eastern Finland) [22, 23]. It remains unknown whether 
there are differences in glioblastoma incidence within the 
different genetic pools in Finland. However, it is known that 
health status and life expectancy vary within Finland. For 
example, individuals living in Northern and Eastern Finland 
have higher rates of strokes, cardiovascular diseases, men-
tal health issues, and accidents than individuals living in 
Southern and Western Finland [24]. Thus, since the current 
median age at the time of glioblastoma diagnosis is approxi-
mately 65 years [4], it is possible that people in Northern 
and Eastern Finland (representing two out of three low-
volume centers) die before diagnosis or are due to relevant 
comorbidities excluded from neurosurgical procedures. As 
a consequence, regional health and comorbidity differences 
combined with unit-specific policy variations may affect 
both the incidence of histopathologically confirmed glio-
blastoma and disease survival.
In the post-Stupp era (2007–2013), the median survival 
times were 9.9 months, 10.1 months, and 9.0 months in the 
high-volume, medium-volume, and low-volume hospitals, 
respectively. Thus, the survival times in the high-volume 
and medium-volume hospitals match those of other Nordic 
countries, while the survival time was slightly shorter in the 
low-volume hospital. For example, a Norwegian study (time 
period: 2004–2007, median age = 64 years) found a median 
survival time of 10.1 months [25] and a Danish study (time 
period: 2009–2014, median age = 66 years) found a median 
survival time of 11.2 months [26]. Moreover, studies from 
the U.S. (Surveillance, Epidemiology, and End Results Pro-
gram [SEER]) have found median survival times of 15 and 
9.7 months [27, 28]. However, it should be noted that only 
one quarter of the U.S. population is covered by the SEER 
and that access to neuro-oncological treatment in the U.S. is 
highly unequal [10]. Thus, due to the major healthcare sys-
tem differences between the Nordic countries and the U.S., 
these numbers cannot be directly compared.
Regarding access to care, Finland has a non-profit, gov-
ernment-subsided healthcare system that provides care for 
all citizens. Still, there are differences in access to primary 
healthcare that could affect access and delay to glioblastoma 
care. For example, access to primary care seems to be at its 
worst in the area of the high-volume hospital in the Helsinki 
metropolitan area (statistical report 16/2019 THL). Further-
more, delays from the time of referral to the time of access 
to specialized care is longest in the area of the high-volume 
Table 4  Relative excess risk 
of death comparison by case 
volume status
Values over one indicates a higher relative risk of death compared to the reference. Values under one indi-
cate a lower relative risk of death compared to the high-volume hospital (reference)
RER relative excess risk of death
*p value for the difference to high-volume adjusted for multiple comparisons
High-volume Medium-volume Low-volume
RER reference RER (95% CI) p value* RER (95% CI) p value*
2000–2006
 All patients 1.0 1.01 (0.85–1.19) 0.948 1.18 (1.00–1.39) 0.089
 ≤ 70 years 1.0 0.99 (0.81–1.20) 0.913 1.15 (0.95–1.38) 0.380
 > 70 years 1.0 1.06 (0.75–1.49) 0.869 1.30 (0.93–1.82) 0.380
2007–2013
 All patients 1.0 0.99 (0.85–1.16) 0.948 1.19 (1.03–1.37) 0.062
 ≤ 70 years 1.0 0.97 (0.81–1.17) 0.869 1.22 (1.04–1.44) 0.141
 > 70 years 1.0 1.06 (0.79–1.41) 0.869 1.11 (0.85–1.45) 0.869
2000–2013
 All patients 1.0 1.02 (0.91–1.15) 0.690 1.19 (1.07–1.32) 0.002
 ≤ 70 years 1.0 1.00 (0.88–1.15) 0.952 1.20 (1.06–1.35) 0.016
 > 70 years 1.0 1.08 (0.87–1.35) 0.655 1.18 (0.95–1.45) 0.266
368 Journal of Neuro-Oncology (2020) 147:361–370
1 3
hospital (statistical report 25/2019 THL). Treatment delays 
such as this should decrease survival; thus, it is possible that 
survival would be even higher in the high-volume hospital 
if access to care was to improve.
Although it was conducted in a completely different 
healthcare system, a recent study from the U.S. reported 
that those glioblastoma patients who travel from low-volume 
centers to high-volume centers have improved outcomes 
compared to those who stay in their local, low-volume cent-
ers [8]. However, such analyses are biased to some extent by 
the fact that those who travel are healthier and more often of 
higher socioeconomic status than those who are not able to 
travel [29]. In Finland, however, specialized care is central-
ized according to the geographical location of the patient’s 
place of residence to one of the five university hospitals. 
Consequently, receiving specialized elective treatment from 
a university hospital in another area has only been possible 
since 2014 and is still exceedingly rare. Thus, it is unclear 
whether travelling longer distances to a high-volume hos-
pital in a country such as Finland would be beneficial or 
cost-effective.
Still, there seems to be a difference in survival between 
hospitals. If this difference is related to lower treatment qual-
ity in low-volume hospitals, it is concerning that nearly half 
(43%) of the Finnish population lives in low-volume hos-
pital regions. However, before obtaining further evidence 
in support of any of the aforementioned speculations, case-
volume-dependent treatment quality differences are a plau-
sible explanation for why both the incidence of operated 
glioblastomas and survival were highest in the high-volume 
center. This view of treatment-quality-related disparities is 
also supported by the results of previous studies [5–8].
Strengths and limitations
In comparison to previous studies [5–7], our study results 
are perhaps more generalizable. As mentioned above, the 
major strength of cancer studies performed in ethnically 
homogeneous Finland is the fact that Finland has a gov-
ernment-subsided healthcare system, providing affordable, 
equal care to all citizens regardless of factors such as per-
sonal insurance. Thus, the noted differences were unex-
pected as they were less likely to relate to racial, ethnic, or 
socioeconomic disparities in the Finnish healthcare setting 
than in other settings. Furthermore, we have previously vali-
dated the FCR with regard to accuracy in identifying glio-
blastoma [4], making this nationwide register-based study 
highly reliable. Still, given the rather unique healthcare 
system in Finland, our results may be less generalizable to 
countries with more unequal healthcare systems. Moreover, 
we analyzed the results separately for two age groups and 
two time periods; this deepened our understanding of the 
case-volume-dependent disparities. Finally, the fact that the 
three low-volume hospitals were geographically scattered, 
further supports the view that the reported differences were 
likely unrelated to demographic differences.
However, the present study also had some limitations that 
should be mentioned. First, the FCR does not contain treat-
ment data (e.g. biopsy vs. resection; extent of resection); 
thus, we were unable to compare treatments in greater detail. 
Second, the FCR does not contain data regarding adjuvant 
chemotherapy and radiation therapy. An internal analysis 
from the high-volume hospital showed that one out of every 
three elderly patients and nine out of every ten young-to-
middle-aged patients received adjuvant radiotherapy with 
concomitant temozolomide [4]. However, how many patients 
received adjuvant treatments in the middle-volume and low-
volume hospitals remain unclear. Furthermore, differences in 
geography and travelling distances between the high, middle, 
and low-volume centers may have affected the actual treat-
ment regimen received by patients following histopathologi-
cal diagnosis. Third, the FCR did not record tumor genet-
ics during the study period (e.g.,  O6-methylguanine-DNA 
methyltransferase methylation). Thus, it is possible, albeit 
unlikely, that differences in tumor genetics between cohorts 
also played a part in our results. Fourth, we only included 
patients with histopathological diagnoses of glioblastoma. 
Thus, our survival and incidence numbers did not include 
those who died before receiving a histopathological diagno-
sis (i.e., those not undergoing resection or biopsy).
Conclusion
We found a significant association between higher case vol-
ume and improved survival rates of glioblastoma patients 
undergoing treatment in academic hospitals. We also found 
notable differences in the age-adjusted incidences of his-
topathologically diagnosed glioblastoma within Finland, 
indicating that diagnostic policies may be more aggressive 
in high-volume hospitals. Future studies should address not 
only treatment policy deviations but also access to health-
care and patient pathways (pre and post-clinical diagnosis).
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